AXIN1
AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer, Skin cancer and 5 more.
Overview
Component of the beta-catenin destruction complex required for regulating CTNNB1 levels through phosphorylation and ubiquitination, and modulating Wnt-signalling. Controls dorsoventral patterning via two opposing effects; down-regulates CTNNB1 to inhibit the Wnt signalling pathway and ventralise embryos, but also dorsalises embryos by activating a Wnt-independent JNK signalling pathway. In Wnt signalling, probably facilitates the phosphorylation of CTNNB1 and APC by GSK3B.
Open Targets scores its association with cancer at 0.86 (direct and indirect evidence; datatypes genetic literature 0.61, affected pathway 0.94, literature 0.97, genetic association 0.71, somatic mutation 0.93). IntOGen calls it a driver in 9 cohorts (0 activating, 9 loss-of-function), covering Oesophageal Adenocarcinoma, Glioblastoma Multiforme, Hepatocellular Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer, Skin cancer and 5 more.
- 1 · What it is
AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
Component of the beta-catenin destruction complex required for regulating CTNNB1 levels through phosphorylation and ubiquitination, and modulating Wnt-signalling.
- 3 · How drugs use it
No product in this corpus aims at AXIN1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:903 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15169 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000103126 (association with cancer (MONDO_0004992) 0.86; per-cancer scores at or above 0.5: hepatocellular carcinoma 0.79, melanoma 0.55, skin cancer 0.55, lung cancer 0.54, leukaemia 0.50 (GraphQL API, CC0)); IntOGen AXIN1 (driver in 9 cohorts (Act 0, LoF 9); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Component of the beta-catenin destruction complex required for regulating CTNNB1 levels through phosphorylation and ubiquitination, and modulating Wnt-signalling. Controls dorsoventral patterning via two opposing effects; down-regulates CTNNB1 to inhibit the Wnt signalling pathway and ventralise embryos, but also dorsalises embryos by activating a Wnt-independent JNK signalling pathway. In Wnt signalling, probably facilitates the phosphorylation of CTNNB1 and APC by GSK3B. Enhances TGF-beta signalling by recruiting the RNF111 E3 ubiquitin ligase and promoting the degradation of inhibitory SMAD7. Also a component of the AXIN1-HIPK2-TP53 complex which controls cell growth, apoptosis and development. Facilitates the phosphorylation of TP53 by HIPK2 upon ultraviolet irradiation. Location: Cytoplasm; Nucleus; Membrane; Cell membrane (UniProt). Locus 16p13.3 (HGNC).
- Hepatocellular carcinoma: Open Targets association 0.79 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 7 cohorts (HCC)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.54 with lung cancer (MONDO_0008903)
- Leukaemia: Open Targets association 0.50 with leukaemia (MONDO_0005059)
- Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 9 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"AXIN1" OR ABSTRACT:"AXIN1" OR TITLE:"axin 1" OR ABSTRACT:"axin 1" OR TITLE:"Axin-1" OR ABSTRACT:"Axin-1" OR TITLE:"PPP1R49" OR ABSTRACT:"PPP1R49") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AXIN1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNUTM1
Shares Oesophageal and junctional adenocarcinoma, Lung cancer (all types), Skin cancer (all types), Oesophageal cancer.
- TargetCDX2
Shares Oesophageal and junctional adenocarcinoma, Lung cancer (all types), Skin cancer (all types), Oesophageal cancer.
- TargetKAT6A
Shares Oesophageal and junctional adenocarcinoma, Lung cancer (all types), Skin cancer (all types), Oesophageal cancer.
- TargetIL7R
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Oesophageal cancer.
- TargetNUP98
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), IntOGen.
- TargetLZTR1
Shares Lung cancer (all types), Skin cancer (all types), Glioma & glioblastoma, Hepatocellular carcinoma.
- TargetAFF4
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, IntOGen.
- TargetRPL5
Shares Leukaemia (all types), Skin cancer (all types), Glioma & glioblastoma, IntOGen.